Tibor Csöszi

Oct 28, 2024 | acsjournals.onlinelibrary.wiley.com | Peter O’Donnell |Yohann Loriot |Tibor Csöszi |Nobuaki Matsubara

INTRODUCTION Approximately 30%–50% of patients with advanced urothelial carcinoma (UC) are ineligible to receive cisplatin-based chemotherapy because of baseline characteristics such as advanced age, renal dysfunction, poor performance status, and other medical comorbidities.1, 2 Although numerous patients in this population can still receive carboplatin-based treatment, many are deemed ineligible for any cytotoxic platinum-based chemotherapy by their treating physicians.3, 4 Because no...